alirocumab + atorvastatin

This is a **combination regimen** of alirocumab and atorvastatin used in the management of hypercholesterolemia, typically in adults with high or very high cardiovascular risk who require additional reduction of LDL cholesterol beyond what is achieved with statin therapy alone. **Alirocumab** is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), leading to increased clearance of LDL cholesterol from the bloodstream. **Atorvastatin** is a small molecule HMG-CoA reductase inhibitor (statin) that reduces cholesterol synthesis in the liver, also lowering LDL cholesterol. When used together, this combination provides significantly greater reductions in LDL cholesterol compared to either increasing the statin dose or combining atorvastatin with other non-statin oral lipid-lowering agents. This regimen is especially considered for patients who do not achieve LDL-C goals with maximally tolerated statin therapy[1][2][3].

Brand names

PraluentLipitor

Other names

INTENSITY-LOW regimenAlirocumab and Atorvastatin combination